Mangham D C, Davie M W, Grimer R J
Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK.
Bone. 2009 Mar;44(3):431-6. doi: 10.1016/j.bone.2008.11.002. Epub 2008 Nov 19.
Paget's disease is presenting at older ages, with a trend to monostotic disease, associated with lower serum total alkaline phosphatase (serum total ALP) levels. Sarcomatous transformation is a rare complication, which only half a century ago had a median age of presentation of less than 60 years. We have investigated whether sarcomatous change exhibits increasing age at presentation, whether the trend to monostotic Paget's disease exists, whether male predominance in sarcoma still continues and explored factors that might affect survival.
Notes of all patients from the Royal Orthopaedic Hospital, Birmingham primary malignant bone tumour registry were reviewed and all cases of Pagetic sarcoma since 1975 extracted. In addition to basic demographic data, mode of presentation, skeletal involvement by Paget's disease, history of treatment, presence of pulmonary metastases, serum total ALP levels and survival were obtained.
Unequivocal Pagetic sarcoma was identified in 32 patients (23 M, 9 F). Age at presentation was 73.8 years with no sex difference and with known pre-existing Paget's disease in 42%. Only 15% had received any specific Paget's disease treatment. Serum total ALP was not invariably markedly elevated (compared with non-sarcomatous disease) and was related to the number of skeletal sites, but not to the sarcoma histological subtype. Paget's disease was monostotic in 46%. Pagetic sarcoma fell from 23% to 8% of primary bone sarcoma referrals in patients aged over 50 years between the decades 1986-1995 and 1996-2005. Median survival remained poor at 0.66 years. Survival of greater than 2 years occurred in 4 patients, one of whom with a low grade Pagetic sarcoma being alive at 12 years follow up.
The proportion of Paget's disease patients with sarcoma has fallen steadily since Paget's original report and is now about 0.3%, the decline predating availability of effective therapy. Sarcoma is not necessarily associated with very high serum total ALP. It is present amongst polyostotic cases in the expected proportion suggesting that more widespread skeletal involvement by Paget's disease is not a significant risk factor for malignant transformation. Sarcoma is presenting later concurrent with the advancing age of non-malignant disease, but male predominance continues. Pagetic sarcoma is now rare, continues to have a poor prognosis and is often the presenting feature of the disease.
佩吉特病多在老年发病,呈单骨型疾病趋势,血清总碱性磷酸酶(血清总ALP)水平较低。肉瘤样变是一种罕见的并发症,仅在半个世纪前,其发病中位年龄还不到60岁。我们研究了肉瘤样变的发病年龄是否增加,单骨型佩吉特病的趋势是否存在,肉瘤中男性占主导的情况是否仍持续,并探讨了可能影响生存的因素。
回顾了伯明翰皇家骨科医院原发性恶性骨肿瘤登记处所有患者的病历,并提取了自1975年以来所有佩吉特肉瘤病例。除了基本人口统计学数据外,还获取了临床表现方式、佩吉特病的骨骼受累情况、治疗史、肺转移情况、血清总ALP水平和生存情况。
明确诊断为佩吉特肉瘤的患者有32例(男性23例,女性9例)。发病年龄为73.8岁,无性别差异,42%的患者有已知的佩吉特病病史。只有15%的患者接受过任何针对佩吉特病的特异性治疗。血清总ALP并非总是显著升高(与非肉瘤性疾病相比),且与骨骼受累部位数量有关,但与肉瘤组织学亚型无关。46%的佩吉特病为单骨型。在1986 - 1995年和1996 - 2005年这两个十年间,50岁以上患者中,佩吉特肉瘤在原发性骨肉瘤转诊病例中的比例从23%降至8%。中位生存期仍然很差,为0.66年。4例患者生存期超过2年,其中1例低级别佩吉特肉瘤患者在随访12年时仍存活。
自佩吉特最初报告以来,佩吉特病合并肉瘤的患者比例稳步下降,目前约为0.3%,这种下降早于有效治疗方法的出现。肉瘤不一定与血清总ALP非常高相关。它在多骨型病例中的比例符合预期,这表明佩吉特病更广泛的骨骼受累并非恶变的重要危险因素。肉瘤的发病年龄随着非恶性疾病患者年龄的增长而推迟,但男性占主导的情况仍持续。佩吉特肉瘤现在很罕见,预后仍然很差,且往往是该病的首发特征。